

BIOCON BIOLOGICS ITALY S.R.L.
BALANCE SHEET AS AT MARCH 31, 2024

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2024</u>
ASSETS		
Current assets		
Financial assets		
(i) Trade receivables	1	15
Total current assets		15
TOTAL		15
EQUITY AND LIABILITIES		
Equity		
Equity share capital	2	15
Total equity		15
Current liabilities		
Total current liabilities		-
TOTAL		15

BIOCON BIOLOGICS ITALY S.R.L.**STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended
	March 31, 2024
Income	
Revenue from operations	-
Other operating income	-
Total revenue (I)	<u>-</u>
Expenses	
Purchases of traded goods	-
Changes in inventories of traded goods	-
Employee benefits expense	-
Depreciation	-
Other expenses	-
Total expenses (II)	<u>-</u>
Profit before tax	<u>-</u>
Tax expense	
Current tax	-
Deferred Tax	-
Total tax expense	<u>-</u>
Profit for the period	<u><u>-</u></u>

BIOCON BIOLOGICS ITALY S.R.L.**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2024
I Cash flows from operating activities	
Profit after tax	-
<u>Adjustments to reconcile profit before tax to net cash flows:</u>	
Operating profit before working capital changes	-
Movements in working capital	
Decrease/(Increase) in trade receivables	(15)
Cash (used)in operations	(15)
Direct taxes paid	-
Net cash flow (used in) operating activities	(15)
Net cash flow (used in) investing activities	-
III Cash flows from financing activities	
Proceeds from issue of equity shares	15
Net cash flow generated from financing activities	15
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	-
VIII Cash and cash equivalents at the end of the year (IV + V + VI)	-
Reconciliation of cash and cash equivalents as per statement of cash flow	
Cash and cash equivalents	
Balances with banks - on current accounts	-
- on deposit accounts	-
Cash on hand	-
Book overdraft	-
Total cash and cash equivalents	-

BIOCON BIOLOGICS ITALY S.R.L.

Notes to financial statements for the period ended March 31, 2024

(All amounts in EUR Thousands, except share data and unless otherwise stated)

March 31, 2024

1. Trade receivables

Other Receivables

Outstanding for a period less than six months from the date they are due for payment
Unsecured, considered good

15

15

2. Share capital

1 Equity share of EUR 15,000 each

15

15
